AFP via Getty Images

White House health director Dr. Anthony Fauci said Americans will need "more vaccines," a day after Pfizer CEO Albert Bourla said a fourth booster is "necessary".

In an interview with CNBC on Tuesday, Fauci was asked how many more mRNA injections will be needed.

"The answer is: we don't know... it is likely that we're not done with this when it comes to vaccines," Fauci said, before adding that people are still dying from COVID.

According to CNBC, the U.S. is still recording more than 1,200 deaths per day from the coronavirus. But most cities and states have ended COVID restrictions.

"Everybody wants to return to normal, everybody wants to put the virus behind us in the rearview mirror, which is, I think, what we should aspire to," said Fauci.

On Sunday, Pfizer CEO Albert Bourla, a licensed veterinarian, told NBC's "Meet the Press" that a fourth booster shot "is necessary... right now."

AFP via Getty Images

Bourla (right) said a fourth booster is necessary because immunity begins to wane three to four months after the third booster.

Last week, Bourla said that data for a fourth booster shot will be submitted to the U.S. Food & Drug Administration (FDA).

Stephane Bancel, the CEO of Moderna, also said last week that a fourth vaccine booster is in the works.

Pfizer hopes to submit data to the FDA on a vaccine for children under 5 years old by next month. The shots could be available for infants and toddlers as early as May.

Dr. Fauci and members of Congress own stocks in Moderna or Pfizer.

Pfizer reported revenue of $37 billion from sales of its mRNA vaccines in 2021, and expects revenues of $92 billion in 2022.

BRENDAN SMIALOWSKI/AFP via Getty Images

Pfizer CEO Albert Bourla (right) said a fourth booster shot is "necessary" due to "waning effectiveness" of the third shot.

Mr. Bourla, a licensed veterinarian, said a 4th dose is needed during an appearance on NBC's "Meet the Press" on Sunday.

"Right now, the way that we have seen, it is necessary, a fourth booster right now," Bourla said.

"The protection that you are getting from the third, it is good enough, actually quite good for hospitalizations and deaths. It's not that good against infections, but doesn't last very long. But we are just submitting those data to the FDA and then we will see what the experts also will say outside Pfizer."

Photo may have been deleted

The Ad Council

By coincidence, triple vaccinated former President Barack Obama announced his breakthrough COVID case on Twitter the same day.

Pfizer is reportedly testing a vaccine that would work against COVID variants that haven't been discovered yet.

Pfizer hopes to submit data to the FDA on a vaccine for children under 5 years old by next month, which could make the shots available for infants and toddlers as early as May.

Pfizer reported revenue of $37 billion from sales of its mRNA vaccines in 2021. The pharma corporation expects revenues of $92 billion in 2022.

Marko Geber / DigitalVision

Pfizer-BioNTech is testing a 3-dose vaccine for 2-5 year olds after data showed the 2-dose mRNA vaccines were ineffective in that age group.

The extended research will delay mRNA vaccines for 2-5 year olds until 2022, Pfizer said in a statement on Friday.

The announcement means Pfizer won't have to present data to regulators until the first half of 2022, NBC News reports.

ER Productions Limited

Earlier this month, Pfizer CEO Albert Bourla, a Greek veterinarian, said the company would have data on 2-5 year olds by the end of the year.

In a news release on Friday, Pfizer said two doses generated a strong immune response in children under 2, but not in children ages 2 to under 5.

Library / IAN HOOTON

"We have decided to modify each of the pediatric studies to incorporate a third dose to the series and seek licensure for a three-dose series rather than a two-dose series as originally anticipated," Kathrin Jansen, Pfizer's head of vaccine research, said on a conference call with investors on Friday.

Photo may have been deleted

Photo may have been deleted

Twitter

Pfizer CEO Albert Bourla, a Greek veterinarian, said a fourth Covid-19 booster shot will be necessary to combat the mild symptoms of the Omicron variant.

In an interview with CNBC on Wednesday, Bourla cited clinical research that shows the Omicron variant can suppress antibodies produced by the mRNA vaccine.

"When we see real-world data... I think we will need a fourth dose," Bourla told CNBC.

Photonews via Getty Images

Pfizer's attorneys sparked outrage when they asked a court to delay releasing their clinical research and vaccine data for 55 years.

Bourla, a veterinarian, previously projected a fourth shot would be required 12 months after the third booster shot and that booster shots will be required annually.

"With omicron we need to see because we have very little information. We may need it faster," he said.

Bourla said his vaccines have saved the global economy "trillions of dollars." He suggested companies that enforce vaccine mandates will reap "financial reward."

"I think it's a strong incentive for innovation for the next pandemic," Bourla said. "That people will see that if they step up to the game to bring something that saves lives, that saves it money, there's also financial reward."

He added: "We didn't do it for that, but I think it's a good thing that there is a financial reward.

Pfizer is expected to earn over $35 billion in mRNA vaccine sales this year.

Twitter users slammed Bourla's 4th dose prediction as a need for a "fourth yacht."